Analyst/Investor presentation

July 31, 2026 To, To, Listing Operation Department Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Bandra Kurla Dalal Street, Mumbai-400001 Complex, Bandra (East), Mumbai-400051 (Scrip Code: 544644) (SYMBOL: CORONA) Dear Sir / Madam, Sub.: Presentation to Analyst / Investor In continuation to our letter dated July 22, 2026 and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the investor presentation on the performance of the Company for the quarter ended June 30, 2026. You are requested to take note of the above. Thanking you. Yours faithfully, For CORONA Remedies Limited Chetna Dharajiya Company Secretary and Compliance Officer Encl.: A/a CORONA Remedies Limited Investor Presentation: July 2026 Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by CORONA Remedies Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness Contents Operational & Financial Performance Financial & Operational Performance for Q1 FY27 About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Annexures Management Team and Historical Financial Performance Key Highlights for Q1FY27 Financial Highlights - Q1FY27(Y-o- Return Ratios Key Highlights  Fastest growing company in top INR 422.4 Cr 50.2% 30 Pharma companies in IPM REVENUE MAT June-26 & Quarter ended +21.9% ROCE# June-26. [1]  Improved our Rank to 26th in MAT June-26 from 27th in MAT March 2026 in IPM [1] INR 93.1 Cr 34.0% EBITDA  Renewed EU-GMP certification for +33.5% the Oral Solid Dosage facility at ROE# 22.0% EBITDA Margin (+190 bps) Bhayla plant in May 2026.  Inaugurated Hormone Facility at Bhayla with EU-GMP certification INR 60.1 Cr in June 2026 ₹9.8/- +30.1%  Chronic and sub-chronic therapies EPS* contribute ~73.4% in Q1FY27. 14.2% PAT Margin (+90 bps) #Annualised *Not Annualised [1] Pharmatrac 4 Commercialized India's Most Advanced EU-GMP Approved Women's Hormone Manufacturing Facility Key Highlights Growing Need for Women's Healthcare Increasing hormonal disorder, demand for fertility care, focus on menopause management and hormone replacement therapies State of the Art Manufacturing Ecosystem Multi dosage forms including tablets, soft gel capsules, ointments and gels within a single specialized manufacturing ecosystem. Manufacturing Technologies Facility incorporates next-generation manufacturing technologies and digital process controls to ensure product consistency, precision and operational excellence Spread across One Lakh sq. ft; facility has an annual manufacturing capacity of 194 million tablets/capsules and 1.5 million ointments/gels. Consolidated Profit & Loss Statement Profit and Loss (₹ Crores) Q1FY27 Q1FY26 Y-o-Y Revenue from Operations 422.4 346.5 21.9% Gross Margin (%) 81.6% 81.0% Employee Cost 122.1 97.4 Other Expenses 129.7 113.5 EBITDA 93.1 69.8 33.5% EBITDA Margin (%) 22.0% 20.1% 190 bps Depreciation & Amortization 13.2 8.9 Other Income 3.2 2.0 Finance Cost 2.7 2.0 Share in Profit/(loss) in Associate 0.0 -0.2 Profit before tax 80.4 60.7 Tax Expense 20.3 14.5 Profit After Tax 60.1 46.2 30.1% Profit After Tax Margin (%) 14.2% 13.3% 90 bps Contents About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q1 and FY27 Annexures Management Team and Historical Financial Performance CORONA’s 3C Philosophy Culture • Ruthless Execution • Internal Promotion • Adaptability • Humbleness Courage CORONA’s • Accepting Mistakes 3C and improving • Robust Inorganic Philosophy Opportunities Commitment • Global Quality Products • Value Creation for Stakeholders • Long Term Sustainable Growth Journey over the years In -licensing Acquisition of 7 brands arrangement with from Bayer Zydus Ferring Pharma Ltd Pharmaceuticals Listing on NSE & BSE in Private Limited to December 2025 market certain products ReceivedEAEU GMP Launch of 1st under women’s health Founded in 2004 accreditation for the cardiological division: and urology and launch of first manufacturing plant at Wellness Launch of division division, later Ahmedabad, Gujarat Purchased the brands Radiance(cardio- named as Acquisition of Wokadine Stelbid and Vitneurin diabetic) & Solaris ‘Pioneer’ division from Dr. Reddy’s from Glaxo Group (gynecology) in 2010 Laboratories Ltd Limited 2004 2005-12 2013-17 2018-21 2022 2023-24 2025-26 2026-27 Launch of division Renewed EU-GMP Launch of multispecialty Acquisition of 6 brands Blaze (urology) certification for the division Xemxin 2005 for sale in India from Purchased the brand Oral Solid Dosage and Aarush in 2008 Abbott India Limited Myoril(in India) from facility at Bhayla plant Commenced production Investment in La Sanofi Healthcare in May 2026 at 1st manufacturing plant Chandra Pharma lab India Private Inaugurated Hormone at Solan, Himachal Private Limitedfor Limited Facility at Bhayla with Pradesh backward integration ReceivedEU GMP EU-GMP certification Entry into women’s into APIs accreditation for the in June 2026 healthcare bus [Showing first 8,000 characters — download PDF for full document]